Free tool
Drug Trial Radar: Psychiatry
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
69
Recruiting, industry sponsors, Psychiatry, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed907
69 trials
Showing 1 to 25, recently updated first.
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT05303064 · 220 participants (planned) · Start Jun 30, 2022 · Primary completion Dec 2027
Drug: OLZ/SAM; Olanzapine · For: Schizophrenia; Bipolar I Disorder
Sites: Dothan, Alabama; Little Rock, Arkansas; Encino, California · 47 sites in all
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06963021 · 200 participants (planned) · Start May 30, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Chino, California; Los Angeles, California; Stanford, California · 39 sites in all
- Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06786624 · 200 participants (planned) · Start Jan 22, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Garden Grove, California; Orange, California · 30 sites in all
- NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06911112 · 200 participants (planned) · Start Mar 31, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Bryant, Arkansas; Cerritos, California · 42 sites in all
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06929273 · 450 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 13, 2028
Drug: KarXT; Lithium and 2 more · For: Bipolar Disorder Type I With Mania
Sites: Glendale, Arizona; Scottsdale, Arizona; Tucson, Arizona · 191 sites in all
- A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.Pivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT04777357 · 338 participants (planned) · Start Apr 28, 2021 · Primary completion Mar 2027
Drug: Cariprazine; Placebo · For: Depression; Bipolar I Disorder
Sites: Bentonville, Arkansas; Anaheim, California; Beverly Hills, California · 87 sites in all
- A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07759128 · 576 participants (planned) · Start Jul 28, 2026 · Primary completion Dec 6, 2028
Drug: SEP-363856 · For: Generalized Anxiety Disorder
Sites: Saraland, Alabama; Tucson, Arizona; Encino, California · 27 sites in all
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPivotal-lookingRecruiting
Cybin IRL LimitedIndustry
NCT06793397 · 330 participants (planned) · Start Dec 10, 2025 · Primary completion Jun 7, 2027
Drug: CYB003 · For: Major Depressive Disorder (MDD); Depression in Adults; Depression - Major Depressive Disorder and 3 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Little Rock, Arkansas · 79 sites in all
- Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsPivotal-lookingRecruiting
Minerva NeurosciencesIndustry
NCT07565428 · 380 participants (planned) · Start Apr 23, 2026 · Primary completion Dec 2027
Drug: Roluperidone; risperidone and 3 more · For: Negative Symptoms of Schizophrenia
Sites: Bellflower, California; Culver City, California; Garden Grove, California · 13 sites in all
- Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderPivotal-lookingRecruiting
COMPASS PathwaysIndustry
NCT07570654 · 300 participants (planned) · Start Sep 14, 2026 · Primary completion Nov 2028
Drug: COMP360 psilocybin · For: PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms and 1 more
Sites: Tucson, Arizona; Irvine, California; Los Angeles, California · 20 sites in all
- A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07767903 · 384 participants (planned) · Start Aug 6, 2026 · Primary completion Oct 25, 2028
Drug: SEP-363856; Placebo · For: Generalized Anxiety Disorder
Sites: Phoenix, Arizona; Los Angeles, California; Redlands, California · 21 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07288567 · 166 participants (planned) · Start Jan 29, 2026 · Primary completion Dec 18, 2029
Drug: KarXT · For: Schizophrenia
Sites: Anaheim, California; Chino, California; Culver City, California · 36 sites in all
- Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant SchizophreniaPivotal-lookingRecruiting
Newron Pharmaceuticals SPAIndustry
NCT07184619 · 400 participants (planned) · Start Jan 23, 2026 · Primary completion Mar 31, 2027
Drug: Evenamide 15 mg bid; Placebo · For: Treatment-resistant Schizophrenia
Sites: Los Angeles, California; Miami, Florida; Atlanta, Georgia · 25 sites in all
- A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07786454 · 1,120 participants (planned) · Start Oct 8, 2026 · Primary completion May 26, 2029
Drug: SEP-363856 · For: Generalized Anxiety Disorder
Sites: Jacksonville, Florida; Orlando, Florida; Jamaica, New York · 4 sites in all
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06951711 · 274 participants (planned) · Start Jun 13, 2025 · Primary completion Nov 2, 2026
Drug: KarXT · For: Bipolar Disorder Type I With Mania or Mania With Mixed Features
Sites: Little Rock, Arkansas; Rogers, Arkansas; Culver City, California · 86 sites in all
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)Pivotal-lookingRecruiting
Definium Therapeutics US, Inc.Industry
NCT07592689 · 165 participants (planned) · Start May 10, 2026 · Primary completion Sep 2027
Drug: DT120 · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Orange, California; San Diego, California · 26 sites in all
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07717892 · 468 participants (planned) · Start Jun 25, 2026 · Primary completion Jun 30, 2028
Drug: Solriamfetol Dose A; Solriamfetol Dose B and 1 more · For: ADHD
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 31 sites in all
- A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsPivotal-lookingRecruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
NCT07424404 · 400 participants (planned) · Start Apr 7, 2026 · Primary completion Mar 8, 2030
Drug: KarXT; KarX-EC · For: Schizophrenia; Autism-Related Irritability
Sites: Dothan, Alabama; Phoenix, Arizona; Anaheim, California · 105 sites in all
- A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07759154 · 80 participants (planned) · Start Sep 1, 2026 · Primary completion May 27, 2027
Drug: Centanafadine XR · For: Attention-deficit/Hyperactivity Disorder; Emotional Dysregulation
Sites: Gainesville, Florida; Jacksonville, Florida; Maitland, Florida · 16 sites in all
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07717879 · 468 participants (planned) · Start Jul 6, 2026 · Primary completion Jun 30, 2028
Drug: Solriamfetol Dose A; Solriamfetol Dose B and 1 more · For: ADHD
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 32 sites in all
- A Study of Brenipatide in Adult Participants With Major Depressive DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07412756 · 1,000 participants (planned) · Start Feb 9, 2026 · Primary completion Feb 2028
Drug: Brenipatide; Placebo · For: Depressive Disorder, Major
Sites: Moorpark, California; Orange, California; New Haven, Connecticut · 180 sites in all
- A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive DisorderPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07573176 · 600 participants (planned) · Start Apr 30, 2026 · Primary completion Aug 24, 2028
Drug: Seltorexant; Placebo · For: Depressive Disorder, Major
Sites: Bryant, Arkansas; Bellflower, California; Glendale, California · 53 sites in all
- A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07716098 · 348 participants (planned) · Start Jul 23, 2026 · Primary completion Dec 27, 2028
Drug: Esketamine 56 mg; Esketamine 84 mg and 1 more · For: Depressive Disorder, Treatment-Resistant
Sites: Redlands, California; San Diego, California; Farmington, Connecticut · 39 sites in all
- A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07227454 · 258 participants (planned) · Start Jan 8, 2026 · Primary completion Apr 9, 2031
Drug: Esketamine; Midazolam · For: Depressive Disorder, Major
Sites: Birmingham, Alabama; New Haven, Connecticut; Washington D.C., District of Columbia · 49 sites in all
- A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD TreatmentPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT07856420 · 705 participants (planned) · Start Sep 29, 2026 · Primary completion Sep 20, 2030
Drug: JNJ-99245354; Placebo · For: Generalized Anxiety Disorder
Sites: Temecula, California; Miami, Florida; Springfield, Massachusetts · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.